TECENTRIQ + CARBOPLATIN/ETOPOSIDE
A proven connection in 1L SCLC
TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer
Setting the standard of care in SCLC
TECENTRIQ was the first treatment advance in SCLC in over 20 years, showing a significant survival benefit in a hard-to-treat patient population.2
IMpower133: A Phase 3 efficacy trial in first-line ES-SCLC2
A Phase 3 study in patients (n=403) with extensive-stage SCLC randomised to receive induction therapy with carboplatin and etoposide in combination with TECENTRIQ or placebo, and then TECENTRIQ or placebo maintenance therapy until disease progression or unacceptable toxicity. Primary endpoints included OS and PFS.2
Significant OS benefit with 30% reduction in risk of death versus carboplatin/etoposide alone2
A statistically significant benefit in median OS in the population treated with TECENTRIQ + carboplatin/etoposide versus carboplatin/etoposide alone (12.3 months vs 10.3 months; HR=0.70; 95% CI: 0.54, 0.91)1,2
TECENTRIQ: First major treatment advance for first-line ES-SCLC in over 20 years3,4
References & Notes
References & Notes
1. TECENTRIQ (atezolizumab), Summary of Product Characteristics. June 2022. Available from: https://www.ema.europa.eu/ (Accessed June 2022).
2. Horn L, Mansfield AS, Szczęsna A, et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.
N Engl J Med. 2018;379:2220-2229.
3. Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549-561.
4. Armstrong SA, Liu SV. Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential. Adv Ther. 2019;36:1826-1832.